Search company, investor...

Stage

Seed VC | Dead

Total Raised

$1.37M

Last Raised

$1.37M

About DR2

DR2 offers next-generation software for demand response. DR-SaaS is software for companies that sell or manage power (utilities, competitive retailers, curtailment service providers, energy consultants and brokers). The software enables these power companies to offer and manage a private-label Demand Response service for their commercial and industrial customers. DR-MassMarket is an integrated software solution for utilities and competitive electric retailers. It combines back-office administration with online marketing tools for engaging small commercial and residential customers and realizing Demand Response.

Headquarters Location

63 Spring Street

Williamstown, Massachusetts, 01267,

United States

888-400-2904

CB Insights
Looking for a leg up on competitive, customer and technology insights?
CB Insights puts confidence and clarity into your most strategic decisions.
See how. Join a demo.
Join a demo
Trusted by the world's smartest companies to:
  • Predict emerging trends
  • See competitors' playbooks
  • Stalk the smart money
  • Identify tomorrow's challengers
  • Spot growing industries
  • Kill analyst data work
Let's see how we can help you!
MicrosoftWalmartWells Fargo
You're one click away from the most comprehensive, unmatched analyst expertise in tech, in-depth private company data and a platform that brings it all together.
Click Now. Join a live demo
Join a demo

Expert Collections containing DR2

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

DR2 is included in 2 Expert Collections, including Energy Management Software.

E

Energy Management Software

610 items

Companies creating software to help manage, optimize, and automate energy management and optimization.

G

Grid and Utility

1,070 items

Companies that are developing and implementing new technologies to optimize the grid and utility sector. This includes, but is not limited to, distributed energy resources, infrastructure security, utility asset management, grid inspection, energy efficiency, grid storage, etc.

Latest DR2 News

Risk Prediction for Arrhythmias by Heart Rate Deceleration Runs in Patients with Chronic Obstructive Pulmonary Disease

Mar 17, 2020

Shao-Jun Yin Department of Respiratory Medicine, Shanghai Sixth People’s Hospital East Affiliated to Shanghai University of Medicine and Health Science, No. 222 Huanhu West Road, Lingang New City, Pudong New Area, Shanghai 201306, People’s Republic of China Tel +862138297762 Email yinshaojun2010@163.com Purpose: Chronic obstructive pulmonary disease (COPD) is associated with increased incidence of arrhythmias, which has been attributed to autonomic dysregulation. Detection of autonomic function may facilitate stratification of COPD patients with respect to their risk of development of arrhythmias. Patients and Methods: A total of 151 COPD patients and 45 non-COPD patients were included in this study. Heart rate deceleration runs (DRs) were detected by dynamic electrocardiogram (ECG); DRs successively occurring in 2, 4, or 8 cardiac cycles were denoted as DR2, DR4, and DR8, respectively. Indicators of arrhythmias including isolated premature atrial contractions (PAC), supraventricular tachycardia (SVT), isolated premature ventricular contractions (PVC), and ventricular tachycardia (VT) were recorded. Occurrence of SVT or PAC ≥ 70/day was considered positive for supraventricular arrhythmias, while positive ventricular arrhythmias category (PVAC) was defined as occurrence of VT or PVC ≥ 10/hour. Results: Compared with non-COPD individuals, COPD patients were associated with increased number of PAC, PVC, higher incidence of PAC > 70/d, SVT, PVAC, and decreased DRs (DR2, DR4, DR8) (P< 0.05). In COPD patients, DRs showed a negative correlation with the incidence of PAC, PVC, SVT, and PVAC (P< 0.05). In receiver operating characteristic curve analysis, all the DRs were found to be significant predictors of PAC > 70/d, SVT, and PVAC. The predictive power of DRs was significantly different from one another with the order ranged as DR4>DR8>DR2 for PAC > 70/d, DR8>DR4>DR2 for SVT, and DR8>DR4>DR2 for PVAC. Conclusion: Our study provides evidence of significant autonomic dysregulation in COPD patients. DRs may serve as a marker of the risk of arrhythmias in COPD patients. Keywords: chronic obstructive pulmonary disease, arrhythmias, deceleration capacity runs, autonomic function, risk stratification This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License . By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms .

DR2 Frequently Asked Questions (FAQ)

  • Where is DR2's headquarters?

    DR2's headquarters is located at 63 Spring Street, Williamstown.

  • What is DR2's latest funding round?

    DR2's latest funding round is Seed VC.

  • How much did DR2 raise?

    DR2 raised a total of $1.37M.

  • Who are the investors of DR2?

    Investors of DR2 include Investors' Circle and SustainVC.

CB Insights
Looking for a leg up on competitive, customer and technology insights?
CB Insights puts confidence and clarity into your most strategic decisions.
See how. Join a demo.
Join a demo
Trusted by the world's smartest companies to:
  • Predict emerging trends
  • See competitors' playbooks
  • Stalk the smart money
  • Identify tomorrow's challengers
  • Spot growing industries
  • Kill analyst data work
Let's see how we can help you!
MicrosoftWalmartWells Fargo

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Join a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.